Clinical Trials

The Early Phase Trials team have decided to suspend recruitment of patients as a result of the evolving situation with COVID-19. We feel that this is appropriate and takes into consideration multiple factors such as the risk to patients associated with increased travelling, additional hospital visits to Addenbrooke's and concerns about the uncertainty of possible side effects associated with experimental therapy (such as myelo- and immuno-suppression or pneumonitis).
 (Last updated 28/07/2021)

Trial Short Name Molecular Target(s)   Patient Population Lead Investigator(s)
in Cambridge
AZD1390 ATM with RT Glioblastoma  G Doherty
Basket of Baskets PD-L1 FGFR Solid tumours with high mutational load/MSI+/- FGFR mutations  R Baird
CALIBRATION PD-L1 Advanced oesophageal malignancies S Pacey
GO40782  NTRK1/2/3 Solid tumour, NTRK1/2/3 gene rearrangements   S Pacey
LEAP-005 PD-1 & RTK 2L/3L TNBC, 4L ovarian cancer, 2L gastric cancer, 2L GBM or 2L BTC, 2L/3L pancreatic cancer B Basu 
PATRIOT ATR Any tumour type – palliative radiotherapy combined with ATR inhibitor  R Baird 
MOv18 igE α-folate receptor  Gyane aFR+ B Basu
Atrium ATR Solid tumours D Jodrell
AZD9833 ER ER+ HER2- advanced breast cancer R Baird
PARADIGM-2 PARP Glioblastoma  S Jefferies
AZD6738  ATR inhibitor Ovarian cancer expansion (Post PARPi, BRCAm, platinum sensitive) all comers D Jodrell/ B Basu
BT1718 MT1-MMP NSCLC, solid tumours with high MT1-MMP expression B Basu
Incyte 86550-102 Multiple PDL1-inhibitor naïve tumours that may respond to immune checkpoint inhibitors, HPV+ tumours, MSI/TMB hi, PD-L1–amplified tumour B Basu
CCS1477 P300/CBP

mCRPC or solid tumours with actionable target related to p300/CBP inhibition [ARID1A/P300/CBP mt; small cell cancer

S Pacey
MCLA-158 LGR5/EGFR Squamous cell head and neck cancer E Smyth/ D Jodrell
Timepoint- MTLCEBPα PD1 and CEBP Advanced lung, ovary, pancreatic, gallbladder, neuroendocrine, breast B Basu